Dossier assessment
Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Children and adolescents 2 years of age and older with active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis)
- Patients who have had an inadequate response or intolerance to one or more prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs): added benefit not proven
- Patients who have had an inadequate response or intolerance to one or more prior biologic disease-modifying antirheumatic drugs (DMARDs): added benefit not proven
Project details
- Project no.
- A23-108
- Commission
- Commission awarded on 13.12.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
- https://doi.org/10.60584/A23-108_en
Connected Projects
-
Dossier assessment
Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Baricitinib (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed